TY  - JOUR
AU  - Safi, S.
AU  - Krzykalla, J.
AU  - Hoffmann, H.
AU  - Benner, A.
AU  - Bischoff, H.
AU  - Eichhorn, M.
AU  - Kriegsmann, M.
AU  - Poschke, I.
AU  - Stögbauer, F.
AU  - Umansky, Ludmila
AU  - Mogler, C.
AU  - Weichert, W.
AU  - Winter, H.
AU  - Beckhove, P.
AU  - Muley, T.
TI  - Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.
JO  - Pulmonology
VL  - nn
SN  - 2531-0429
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2024-00784
SP  - nn
PY  - 2024
AB  - Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 
KW  - Biomarkers (Other)
KW  - Cytokines (Other)
KW  - IL-1β (Other)
KW  - Lung neoplasms (Other)
KW  - Tumor microenvironment (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38614857
DO  - DOI:10.1016/j.pulmoe.2024.03.003
UR  - https://inrepo02.dkfz.de/record/289462
ER  -